AttributesValues
type
value
  • Abstract Endocrine therapy is a systemic therapy and has become the main treatment strategy for patients with estrogen receptor (ER) positive breast cancer. However, tamoxifen resistance has become an insurmountable clinical challenge and the underlying mechanisms are still poorly understood. In this study, we explored the roles of CXCR4 in tamoxifen-treated breast cancer and tamoxifen resistance. Based on Gene Expression Omnibus (GEO) database, high expression of CXCR4 was found to be associated with worse overall survival (HR = 4.646, p < 0.001) and cancer-specific survival (HR = 4.480, p < 0.001) in tamoxifen-treated breast cancer. CXCR4 was also positively correlated with the level of AKT phosphorylation and the resistance to tamoxifen in breast cancer. AMD3100 is a CXCR4 antagonist and was found to decrease p-AKT levels of tamoxifen-resistant cells. The reversal effect of AMD3100 on tamoxifen resistance was also confirmed in vitro and in vivo. Taken together, our study demonstrated that CXCR4 could be a potential prognostic biomarker for tamoxifen-treated breast cancer and the combination of AMD3100 with tamoxifen could be a more efficacious therapeutic strategy for the treatment of tamoxifen resistance.
Subject
  • Sanofi
  • Genetics
  • RTT
  • World Anti-Doping Agency prohibited substances
  • Hormonal antineoplastic drugs
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software